Table 1 Baseline characteristics
All patients N = 177 (%) | DTI ≤ 60 days n = 144 (%) | DTI > 60 days n = 33 (%) | |
|---|---|---|---|
Median age in years (range) | 61 (21–91) | 61 (21–91) | 61 (42–82) |
Gender | |||
Male | 84 (48) | 70 (49) | 14 (42) |
Female | 93 (52) | 74 (51) | 19 (58) |
Race | |||
White | 129 (75) | 105 (76) | 24 (73) |
African American | 30 (18) | 25 (18) | 5 (15) |
Others | 12 (7) | 8 (6) | 4 (12) |
MZL subtype | |||
NMZL | 67 (38) | 54 (38) | 13 (39) |
SMZL | 33 (19) | 29 (20) | 4 (12) |
EMZL | 77 (43) | 61 (42) | 16 (49) |
ECOG PS | |||
0–1 | 142 (92) | 114 (92) | 28 (93) |
≥ 2 | 12 (8) | 10 (8) | 2 (7) |
Stage | |||
1–2 | 18 (10) | 12 (8) | 6 (18) |
3–4 | 159 (90) | 132 (92) | 27 (82) |
BM involvement | |||
No | 57 (40) | 41 (36) | 16 (57) |
Yes | 85 (60) | 73 (64) | 12 (43) |
Not done | 35 | 30 | 5 |
B symptoms | |||
No | 132 (77) | 101 (73) | 31 (97) |
Yes | 39 (23) | 38 (27) | 1 (3) |
LDH > ULN | |||
No | 115 (74) | 90 (73) | 25 (78) |
Yes | 41 (26) | 34 (27) | 7 (22) |
Ki67 > 20% | |||
No | 73 (71) | 58 (72) | 15 (68) |
Yes | 30 (29) | 23 (28) | 7 (32) |
Not tested | 44 | 63 | 11 |
Monoclonal paraprotein | |||
No | 55 (57) | 38 (3) | 17 (71) |
Yes | 42 (43) | 35 (48) | 7 (29) |
Not tested | 80 | 71 | 9 |
WBC (K/uL), median (range) | 6.1 (0.7–151) | 5.9 (0.7–151) | 6.4 (2.5–90.6) |
Hb (g/dL), median (range) | 11.9 (3.7–16.1) | 11.8 (3.7–16.1) | 12.4 (7.7–15.8) |
Serum albumin | |||
Normal | 135 (85) | 109 (86) | 26 (81) |
Low^ | 23 (15) | 17 (14) | 6 (19) |
First-line therapy | |||
BR | 132 (75) | 106 (74) | 26 (79) |
RCHOP | 27 (15) | 23 (16) | 4 (12) |
RCVP | 18 (10) | 15 (10) | 3 (9) |